LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer

Table 1 Univariate and multivariable analyses of factors predictive of poor overall survival in pancreatic cancer patients

Variables	Univariate analysis			Multivariate analysis
	Overall survival	95% confidence interval	P value	Hazard ratio	95% confidence interval	P value
	(Median ± SE,months)	95% confidence interval	P value	Hazard ratio	95% confidence interval	P value
Sex			0.726
Male	10 ± 1.063	7.917–12.083
Female	11 ± 4.433	2.311–19.689
Age(years old)			0.379
<65	11 ± 0.980	9.078–12.922
≥ 65	7 ± 0.833	5.367–8.633
Locations			0.234
Head	10 ± 1.440	7.178–12.822
Body-tail	10 ± 1.571	6.921–13.079
Perineuronal/vascular/lymphatic invasion			0.280
No	11 ± 2.60	5.905–16.095
Yes	10.0 ± 0.957	8.125–11.875
Tumor staging			0.594
T1/T2	10.0 ± 1.201	7.646–12.354
T3/T4	10.0 ± 1.474	7.112–12.888
Lymph node staging			0.049	2.053	1.228–3.433	0.006
N0	10 ± 3.499	3.141–16.859
N1/N2	10 ± 1.533	6.996–13.004
Differential degree			0.002	2.737	1.614–4.644	0.000
High/ moderate	12 ± 2.854	6.406–17.594
Low	6 ± 1.076	3.890–8.110
TNM staging			0.614
I	10 ± 3.177	3.772–16.228
II/III	10 ± 0.867	8.301–11.699
LAT2 expression			0.008	1.912	1.122–3.258	0.017
Low	23 ± 9.142	5.081–40.919
High	9 ± 0.802	7.429–10.571

ISSN: 1756-9966